Tweet Group

Nov 18

Testing & Diagnosis
Masks & PPE
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints | Pfizer
Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in...
Dr. Angela Rasmussen @angie_rasmussen - Wed Nov 18
Here's some more good news. Pfizer/BioNTech's phase 3 trial has concluded after reaching its primary efficacy endpoints, and saw a boost from 90% to 95% efficacy. And this press release at least has more information than the last one. What does it say?…
179 678 Open Tweet
3 expert retweets
Expert replies & quotes
Florian Krammer @florian_krammer - Wed Nov 18
More good news from Pfizer. All efficacy endpoints were met. 94% efficacy in the 65+ group. Let's get this to the people. EUA application 'within days'.…
302 2104 Open Tweet
3 expert retweets
Natalie E. Dean, PhD @nataliexdean - Wed Nov 18
More result from Pfizer/BioNTech. Their trial accrued 170 (!) cases (162 in the placebo group vs. 8 in the vaccine group) for 95% efficacy. 94% in older adults. Incredible to see how quickly the trial has progressed since their first analysis of 94 cases.…
134 877 Open Tweet
Expert replies & quotes
Dr. Tom Frieden @DrTomFrieden - Wed Nov 18
Exciting, encouraging results on Covid vaccine! Supply, immunity duration, protection of frail, safety when millions vaccinated to be seen. Soon, for distribution: fast, fair, fully transparent. But for many more months much better control measures needed.
37 248 Open Tweet
AlbertBourla @AlbertBourla - Wed Nov 18
Very happy to say that we have more good news to share. The final efficacy analysis of @Pfizer's Phase 3 study showed that our #COVID19 vaccine candidate met all of the study's primary efficacy endpoints:…
193 1182 Open Tweet
1 expert retweets